A
A Alcalá
Publications - 11
Citations - 462
A Alcalá is an academic researcher. The author has contributed to research in topics: Melphalan & Vincristine. The author has an hindex of 8, co-authored 11 publications receiving 426 citations.
Papers
More filters
Journal ArticleDOI
Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone
Emilio Montserrat,A Alcalá,Ricardo Parody,Andreu Domingo,Javier García-Conde,Javier Bueno,Carmen Ferrán,Miguel A. Sanz,Manuel Giralt,Daniel Rubio,Isabel Antón,Jordi Estapé,Ciril Rozman +12 more
TL;DR: Patients with advanced chronic lymphocytic leukemia (CLL) (Stage C; anemia and/or thrombocytopenia of nonimmune origin) were randomized to receive either chlorambucil (CLR) plus PDN plus prednisone (PDN) every 2 weeks or cyclophosphamide (600 mg/m2 intravenously, day 6).
Journal ArticleDOI
Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.
J. Bladé,J F San Miguel,M. Fontanillas,A Alcalá,Jesús E. Maldonado,Javier García-Conde,Eulogio Conde,G Conzález-Brito,Moro Mj,M.L. Escudero,J. Trujillo,A Pascual,Rozman C,Jordi Estapé,Montserrat E +14 more
TL;DR: The median survival time of patients with MM who are less than 65 years of age and who respond to initial chemotherapy is 5 years and the importance of ongoing randomized trials to determine the role of HDT in the treatment of younger myeloma patients is stressed.
Journal ArticleDOI
Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
J. Bladé,J F San Miguel,A Alcalá,Jesús E. Maldonado,Miguel-Angel Sanz,Javier García-Conde,Moro Mj,Carmen Alonso,Juan Besalduch,A. Zubizarreta +9 more
TL;DR: Results indicate that combination chemotherapy improves response rate in MM, however, this does not result in a significantly different survival rate, except for patients with IgA myeloma, who survive significantly longer with combination chemotherapy.
Journal ArticleDOI
Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
de la Rubia J,J. Bladé,J.J. Lahuerta,Josep-Maria Ribera,R. Martínez,A Alegre,José García-Laraña,Pascual Fernandez,Anna Sureda,de Arriba F,Dolores Carrera,Juan Besalduch,García Boyero R,Palomera Bernal L,Milagros Hernández,García Pr,Pérez-Calvo J,A Alcalá,Casado Lf,San Miguel J +19 more
TL;DR: In this paper, the impact of first-line chemotherapy with alkylating agents on stem cell collection in multiple myeloma (MM) patients was analyzed, showing that the CD34+ cell yield was lower than 4x10(6)/kg in 388 patients (49%), and equal or greater than 4×10 (6)/ kg in 401 patients (51%).
Journal ArticleDOI
Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL
J. J. Ortega,Josep-Maria Ribera,Albert Oriol,Pilar Bastida,Marcos González,Carlota Calvo,Izaskun Egurbide,J M Hernández Rivas,Concha Rivas,A Alcalá,Juan Besalduch,J. Macia,Santiago Gardella,Mercedes Carnero,J M Lite,F. Casanova,Molina Martínez,M. Fontanillas,Feliu E,J F San Miguel +19 more
TL;DR: Early consolidation seemed to improve the prognosis of children with LR-ALL, but differences in EFS were not significant, and CNS preventive treatment without cranial irradiation was effective in all the groups of ALL patients.